a-gO develops a medical imaging system designed to detect and monitor precursor markers for neurodegenerative diseases like Parkinson's and Alzheimer's. This early detection capability allows for proactive management of these conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Neurodegenerative diseases like Parkinson's and Alzheimer's are difficult to diagnose early, delaying potential interventions. Current diagnostic methods often detect the diseases after significant neurological damage has already occurred. This late detection limits the effectiveness of therapeutic interventions.
Solution
a-gO develops a medical imaging system designed for the early detection and monitoring of precursor markers associated with neurodegenerative diseases. By identifying these markers, the system aims to enable proactive management of conditions like Parkinson's and Alzheimer's. The technology seeks to provide clinicians with the ability to detect subtle changes indicative of disease onset, potentially years before traditional symptoms manifest. This early insight could facilitate timely interventions and personalized treatment strategies. The system aims to improve patient outcomes by enabling earlier and more informed clinical decision-making.
Target Audience
The primary target audience includes neurologists, radiologists, and medical researchers focused on neurodegenerative diseases, as well as hospitals and diagnostic imaging centers.
Features
- Medical imaging system for detecting early markers of neurodegenerative diseases.
- Designed for proactive management of conditions like Parkinson's and Alzheimer's.